DexCom, Inc. (NASDAQ:DXCM) Given Consensus Rating of “Moderate Buy” by Analysts

DexCom, Inc. (NASDAQ:DXCM) has been given an average recommendation of “Moderate Buy” by the twenty-seven analysts that are covering the firm, MarketBeat.com reports. One equities research analyst has rated the stock with a sell rating, three have assigned a hold rating, twenty-one have given a buy rating and two have issued a strong buy rating on the company. The average 12 month price objective among brokers that have issued ratings on the stock in the last year is $88.7083.

A number of brokerages have recently commented on DXCM. TD Cowen reissued a “buy” rating on shares of DexCom in a research note on Friday, July 31st. Benchmark upped their target price on DexCom from $77.00 to $82.00 and gave the company a “buy” rating in a research report on Friday, July 31st. Wall Street Zen lowered shares of DexCom from a “strong-buy” rating to a “buy” rating in a research note on Sunday, May 10th. BTIG Research restated a “buy” rating and set a $90.00 price objective (up from $80.00) on shares of DexCom in a research note on Friday, July 31st. Finally, Mizuho raised their target price on shares of DexCom from $90.00 to $95.00 and gave the stock an “outperform” rating in a report on Friday, July 31st.

DexCom Stock Performance

Shares of DXCM stock opened at $90.80 on Thursday. The company has a debt-to-equity ratio of 0.47, a quick ratio of 1.43 and a current ratio of 1.73. The firm has a market capitalization of $34.26 billion, a price-to-earnings ratio of 35.89, a price-to-earnings-growth ratio of 1.51 and a beta of 1.41. The company has a 50 day moving average price of $75.36 and a 200 day moving average price of $70.09. DexCom has a one year low of $54.11 and a one year high of $91.04.

DexCom (NASDAQ:DXCM) last issued its earnings results on Thursday, July 30th. The medical device company reported $0.70 earnings per share for the quarter, beating analysts’ consensus estimates of $0.61 by $0.09. The firm had revenue of $1.31 billion for the quarter, compared to analysts’ expectations of $1.29 billion. DexCom had a return on equity of 35.94% and a net margin of 20.12%.The firm’s revenue for the quarter was up 13.1% compared to the same quarter last year. During the same quarter last year, the firm earned $0.48 earnings per share. Sell-side analysts anticipate that DexCom will post 2.64 EPS for the current year.

Insider Activity

In other DexCom news, Director Mark G. Foletta sold 2,000 shares of the business’s stock in a transaction on Monday, August 3rd. The stock was sold at an average price of $85.32, for a total transaction of $170,640.00. Following the completion of the transaction, the director owned 48,852 shares in the company, valued at approximately $4,168,052.64. The trade was a 3.93% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Michael Jon Brown sold 1,700 shares of the company’s stock in a transaction dated Monday, June 15th. The stock was sold at an average price of $75.55, for a total transaction of $128,435.00. Following the completion of the sale, the executive vice president directly owned 106,353 shares of the company’s stock, valued at $8,034,969.15. The trade was a 1.57% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last quarter, insiders have sold 101,494 shares of company stock valued at $7,475,168. 0.28% of the stock is owned by company insiders.

Hedge Funds Weigh In On DexCom

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the company. BOKF NA lifted its holdings in DexCom by 175.7% in the 4th quarter. BOKF NA now owns 35,314 shares of the medical device company’s stock valued at $2,344,000 after acquiring an additional 22,505 shares during the last quarter. Stephens Investment Management Group LLC increased its holdings in shares of DexCom by 21.1% in the 4th quarter. Stephens Investment Management Group LLC now owns 1,042,801 shares of the medical device company’s stock valued at $69,211,000 after purchasing an additional 181,701 shares during the period. Eurizon Capital SGR S.p.A. purchased a new stake in DexCom in the 4th quarter worth approximately $3,231,000. Goodman Advisory Group LLC purchased a new stake in shares of DexCom during the fourth quarter worth $1,293,000. Finally, Employees Retirement System of Texas acquired a new stake in shares of DexCom during the 4th quarter valued at about $37,871,000. 97.75% of the stock is owned by institutional investors.

DexCom Company Profile

DexCom, Inc is a medical device company that develops, manufactures and distributes continuous glucose monitoring (CGM) systems for people with diabetes. Its products are designed to provide near real-time glucose readings, trend information and alerts to help patients and clinicians manage insulin dosing and reduce hypoglycemia and hyperglycemia. The company’s offerings combine wearable glucose sensors, wireless transmitters and software applications that deliver data to smartphones, dedicated receivers and cloud-based platforms for remote monitoring.

Founded in 1999 and headquartered in San Diego, California, DexCom has focused its business on advancing CGM technology and expanding clinical use beyond traditional insulin-dependent populations.